SpringWorks Therapeutics, Inc.
DelistedCIK 1773427fmd_14FMZRGFY0SE9AQ7B8SFBSBNQNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Mar 31, 2025, 29 periods
Latest annual · FY2024
Millions- Total revenues
- 192
- Gross profit
- 179
- Operating income
- (278)
- Net income
- (258)
- Free cash flow
- (180)
Latest quarter · Q1 FY2025
Millions- Total revenues
- 49
- Gross profit
- 46
- Operating income
- (81)
- Net income
- (83)
- Free cash flow
- (69)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- n/m
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
SpringWorks Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $191.6 million | $5.4 million | +3,417.3% | 10-K 2025-02-20 · proof |
| Gross profit | $179 million | $5 million | +3,463% | 10-K 2025-02-20 · proof |
| Operating income | -$278.1 million | -$343 million | 10-K 2025-02-20 · proof | |
| Net income | -$258.1 million | -$325.1 million | 10-K 2025-02-20 · proof | |
| Cash from operating activities | -$175.6 million | -$222.8 million | 10-K 2025-02-20 · proof | |
| Free cash flow | -$180.1 million | -$230.2 million | 10-K 2025-02-20 · proof | |
| Total assets | $587.3 million | $725.8 million | -19.1% | 10-K 2025-02-20 · proof |
| Total liabilities | $106.2 million | $99.6 million | +6.6% | 10-K 2025-02-20 · proof |
| Cash and cash equivalents | $69.8 million | $176.1 million | -60.4% | 10-K 2025-02-20 · proof |
- What was SpringWorks Therapeutics, Inc.'s revenue in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported revenue of $191.6 million for fiscal 2024 (the year ended Dec 31, 2024), against $5.4 million the year before (+3,417.3%). Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What was SpringWorks Therapeutics, Inc.'s gross profit in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported gross profit of $179 million for fiscal 2024 (the year ended Dec 31, 2024), against $5 million the year before (+3,463%). Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What was SpringWorks Therapeutics, Inc.'s operating income in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported operating income of -$278.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$343 million the year before. Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What was SpringWorks Therapeutics, Inc.'s net income in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported net income of -$258.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$325.1 million the year before. Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What was SpringWorks Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported cash from operating activities of -$175.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$222.8 million the year before. Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What was SpringWorks Therapeutics, Inc.'s free cash flow in fiscal 2024?
- SpringWorks Therapeutics, Inc. reported free cash flow of -$180.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$230.2 million the year before. Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What are SpringWorks Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, SpringWorks Therapeutics, Inc. reported total assets of $587.3 million, against $725.8 million a year earlier (-19.1%). Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What are SpringWorks Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, SpringWorks Therapeutics, Inc. reported total liabilities of $106.2 million, against $99.6 million a year earlier (+6.6%). Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
- What are SpringWorks Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, SpringWorks Therapeutics, Inc. reported cash and cash equivalents of $69.8 million, against $176.1 million a year earlier (-60.4%). Source: the 10-K filed with the SEC on Feb 20, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1773427&period_type=annual&limit=5"Information only, not investment advice.